Piper Sandler lowered the firm’s price target on Nurix Therapeutics (NRIX) to $32 from $35 and keeps an Overweight rating on the shares after the company reported Q3 earnings. The firm notes Nurix continues to track to pivotal trial for bexobrutideg initiation by year-end this year. Furthermore, last month, Nurix disclosed the design of the pivotal trial in 2L+ CLL which would randomize 400-500 patients to either bexobrutideg or investigator’s choice of three regimens active in CLL. The company plans to provide additional updates from the Phase 1/2 trial at ASH.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating
- Nurix Therapeutics price target lowered to $28 from $30 at Oppenheimer
- Closing Bell Movers: Levi Strauss down 8% after results
- Nurix Therapeutics reports Q3 EPS ($1.03), consensus (85c)
- NRIX Upcoming Earnings Report: What to Expect?